Malaria vaccine candidate reduces disease in children
Tuesday, October 8, 2013 - 10:30
in Health & Medicine
Results from a large-scale Phase 3 trial show that the most clinically advanced malaria vaccine candidate, RTS,S, continued to protect young children and infants from clinical malaria up to 18 months after vaccination. Based on these data, scientists now intend to submit, in 2014, a regulatory application to the European Medicines Agency.